Biotechnology in the Heart of the Capital City
CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries.
Full Year Results 2023
CSL reports 20% profit growth with a full-year net profit of $2.61 billion (1,2).
Minister for Skills and Training visits Bern
Australian Minister for Skills and Training visits CSL Behring in Bern and meets apprentices.
Digital transformation in the biopharma industry
Women in Digital: Learn more from CSL experts in the webinar on 9 June.
New R&D office on the Biopôle campus in Lausanne
To strengthen its R&D foothold in the Romandy, CSL opens a permanent R&D office in one of the most thriving biotech hubs in S…
CSL R&D Switzerland awards Biomedical Science Award
The three winners were honored at the graduation ceremony of the University of Bern. (Pictures: Adrian Moser)
Paul McKenzie visits Wankdorf Stadium
BSC Young Boys warmly welcomed Paul McKenzie, CSL's new CEO and Managing Director.